Evidence map›Paper›PMID 26764160›Full record

ArticleMolecular biology and evolution2016

267 Spanish Exomes Reveal Population-Specific Differences in Disease-Related Genetic Variation.

Joaquín Dopazo, Alicia Amadoz, Marta Bleda, Luz Garcia-Alonso, Alejandro Alemán, Francisco García-García, Juan A Rodriguez, Josephine T Daub, Gerard Muntané, Antonio Rueda and 14 more

Abstract read
In one paragraph

Article in Molecular biology and evolution, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 51 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
51citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

51 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors.

Joaquín DopazoComputational Genomics Department, Centro de Investigación Príncipe Felipe (CIPF), Valencia, Spain Medical Genome Project, Genomics and Bioinformatics Platform of Andalusia (GBPA), Sevilla, Spain Bioinformatics in Rare Diseases (BIER), Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Valencia, Spain Functional Genomics Node, National Institute of Bioinformatics (INB), Valencia, Spain jdopazo@cipf.es gantinolo@us.es.
Alicia AmadozComputational Genomics Department, Centro de Investigación Príncipe Felipe (CIPF), Valencia, Spain.
Marta BledaComputational Genomics Department, Centro de Investigación Príncipe Felipe (CIPF), Valencia, Spain Bioinformatics in Rare Diseases (BIER), Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Valencia, Spain.
Luz Garcia-AlonsoComputational Genomics Department, Centro de Investigación Príncipe Felipe (CIPF), Valencia, Spain.
Alejandro AlemánComputational Genomics Department, Centro de Investigación Príncipe Felipe (CIPF), Valencia, Spain Bioinformatics in Rare Diseases (BIER), Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Valencia, Spain.
Francisco García-GarcíaComputational Genomics Department, Centro de Investigación Príncipe Felipe (CIPF), Valencia, Spain.
Juan A RodriguezInstitut De Biologia Evolutiva, Consejo Superior de Investigaciones Científicas - Universitat Pompeu Fabra, Barcelona, Spain.
Josephine T DaubInstitut De Biologia Evolutiva, Consejo Superior de Investigaciones Científicas - Universitat Pompeu Fabra, Barcelona, Spain.
Gerard MuntanéInstitut De Biologia Evolutiva, Consejo Superior de Investigaciones Científicas - Universitat Pompeu Fabra, Barcelona, Spain.
Antonio RuedaMedical Genome Project, Genomics and Bioinformatics Platform of Andalusia (GBPA), Sevilla, Spain.
Alicia Vela-BozaMedical Genome Project, Genomics and Bioinformatics Platform of Andalusia (GBPA), Sevilla, Spain.
Francisco J López-DomingoMedical Genome Project, Genomics and Bioinformatics Platform of Andalusia (GBPA), Sevilla, Spain.
Javier P FloridoMedical Genome Project, Genomics and Bioinformatics Platform of Andalusia (GBPA), Sevilla, Spain.
Pablo ArceMedical Genome Project, Genomics and Bioinformatics Platform of Andalusia (GBPA), Sevilla, Spain.
Macarena Ruiz-FerrerMedical Genome Project, Genomics and Bioinformatics Platform of Andalusia (GBPA), Sevilla, Spain Department of Genetics, Reproduction and Fetal Medicine, Institute of Biomedicine of Seville, University Hospital Virgen del Rocío/Consejo Superior de Investigaciones Científicas/University of Seville, Sevilla, Spain Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Sevilla, Spain.
Cristina Méndez-VidalDepartment of Genetics, Reproduction and Fetal Medicine, Institute of Biomedicine of Seville, University Hospital Virgen del Rocío/Consejo Superior de Investigaciones Científicas/University of Seville, Sevilla, Spain Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Sevilla, Spain.
Todd E ArnoldResearch and Development, 454 Life Sciences, a Roche Company, Branford, CT, USA.
Olivia SpleissRoche Pharma Research and Early Development, Pharmaceutical Sciences, Roche Innovation Center Basel, Basel, Switzerland.
Miguel Alvarez-TejadoRoche Diagnostics SL, Sant Cugat del Vallès, Spain.
Arcadi NavarroDepartament of Experimental and Health Sciences, Universitat Pompeu Fabra, Barcelona, Spain Institució Catalana de Recerca I Estudis Avançats (ICREA), Barcelona Biomedical Research Park (PRBB), Barcelona, Spain Center for Genomic Regulation (CRG), Barcelona Biomedical Research Park (PRBB), Barcelona, Spain.
Shomi S BhattacharyaMedical Genome Project, Genomics and Bioinformatics Platform of Andalusia (GBPA), Sevilla, Spain Andalusian Molecular Biology and Regenerative Medicine Centre (CABIMER), Sevilla, Spain.
Salud BorregoDepartment of Genetics, Reproduction and Fetal Medicine, Institute of Biomedicine of Seville, University Hospital Virgen del Rocío/Consejo Superior de Investigaciones Científicas/University of Seville, Sevilla, Spain Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Sevilla, Spain.
Javier Santoyo-LópezMedical Genome Project, Genomics and Bioinformatics Platform of Andalusia (GBPA), Sevilla, Spain.
Guillermo AntiñoloMedical Genome Project, Genomics and Bioinformatics Platform of Andalusia (GBPA), Sevilla, Spain Department of Genetics, Reproduction and Fetal Medicine, Institute of Biomedicine of Seville, University Hospital Virgen del Rocío/Consejo Superior de Investigaciones Científicas/University of Seville, Sevilla, Spain Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Sevilla, Spain jdopazo@cipf.es gantinolo@us.es.

Funding

Medical Research Council G0900740Medical Research Council MR/K001744/1
6 · The paper itself

Abstract

Recent results from large-scale genomic projects suggest that allele frequencies, which are highly relevant for medical purposes, differ considerably across different populations. The need for a detailed catalog of local variability motivated the whole-exome sequencing of 267 unrelated individuals, representative of the healthy Spanish population. Like in other studies, a considerable number of rare variants were found (almost one-third of the described variants). There were also relevant differences in allelic frequencies in polymorphic variants, including ∼10,000 polymorphisms private to the Spanish population. The allelic frequencies of variants conferring susceptibility to complex diseases (including cancer, schizophrenia, Alzheimer disease, type 2 diabetes, and other pathologies) were overall similar to those of other populations. However, the trend is the opposite for variants linked to Mendelian and rare diseases (including several retinal degenerative dystrophies and cardiomyopathies) that show marked frequency differences between populations. Interestingly, a correspondence between differences in allelic frequencies and disease prevalence was found, highlighting the relevance of frequency differences in disease risk. These differences are also observed in variants that disrupt known drug binding sites, suggesting an important role for local variability in population-specific drug resistances or adverse effects. We have made the Spanish population variant server web page that contains population frequency information for the complete list of 170,888 variant positions we found publicly available (http://spv.babelomics.org/), We show that it if fundamental to determine population-specific variant frequencies to distinguish real disease associations from population-specific polymorphisms.

Indexed as

ExomeDatabases, Nucleic AcidDiseaseDrug ResistanceGene FrequencyGenetic Predisposition to DiseaseGenetics, PopulationGenetic VariationHumansInternetPharmacogenomic TestingPolymorphism, GeneticSpaindisease variantsexome sequencingpharmacogenomic variants.population variability

Identifiers

PMID26764160
PMCPMC4839216

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.